Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EYPTNASDAQ:LABNASDAQ:QSINASDAQ:SEER On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEYPTEyePoint Pharmaceuticals$7.42+2.5%$5.86$3.91▼$13.99$510.58M1.58828,285 shs1.14 million shsLABStandard BioTools$1.05+4.0%$1.11$0.92▼$2.60$398.81M1.82.13 million shs1.57 million shsQSIQuantum-Si$1.68$1.33$0.61▼$5.77$308.28M2.7110.64 million shs5.35 million shsSEERSeer$2.14+11.5%$1.94$1.56▼$2.63$125.98M1.58341,280 shs386,670 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEYPTEyePoint Pharmaceuticals0.00%+26.94%-1.23%+26.05%-32.68%LABStandard BioTools0.00%+12.30%-13.75%+2.48%-58.27%QSIQuantum-Si0.00%-14.43%+31.75%+27.69%+9.21%SEERSeer0.00%-5.95%-3.66%-4.13%+9.72%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEYPTEyePoint Pharmaceuticals2.2653 of 5 stars3.53.00.00.02.81.70.0LABStandard BioTools2.7621 of 5 stars3.33.00.00.02.43.30.6QSIQuantum-Si2.7314 of 5 stars3.32.00.00.03.82.50.6SEERSeer1.7333 of 5 stars3.01.00.00.02.22.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEYPTEyePoint Pharmaceuticals 3.00Buy$25.38241.98% UpsideLABStandard BioTools 2.50Moderate Buy$2.50138.10% UpsideQSIQuantum-Si 2.67Moderate Buy$3.48106.85% UpsideSEERSeer 2.00Hold$3.0040.19% UpsideCurrent Analyst Ratings BreakdownLatest SEER, EYPT, QSI, and LAB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/29/2025EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.005/19/2025QSIQuantum-SiHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.505/16/2025QSIQuantum-SiAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/16/2025EYPTEyePoint PharmaceuticalsMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$30.00 ➝ $26.005/8/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$33.00 ➝ $27.003/6/2025EYPTEyePoint PharmaceuticalsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$33.00 ➝ $33.003/6/2025EYPTEyePoint PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $22.003/5/2025QSIQuantum-SiNational BanksharesSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$3.653/5/2025QSIQuantum-SiAlliance Global PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEYPTEyePoint Pharmaceuticals$56.04M9.11N/AN/A$5.66 per share1.31LABStandard BioTools$169.69M2.35N/AN/A($1.85) per share-0.57QSIQuantum-Si$3.44M89.54N/AN/A$1.92 per share0.88SEERSeer$15.06M8.36N/AN/A$6.17 per share0.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEYPTEyePoint Pharmaceuticals-$70.79M-$2.41N/AN/AN/A-226.57%-43.01%-31.63%8/6/2025 (Estimated)LABStandard BioTools-$74.66M-$0.35N/AN/AN/A-79.92%-27.05%-15.52%7/30/2025 (Estimated)QSIQuantum-Si-$95.96M-$0.68N/AN/AN/A-3,968.84%-36.96%-33.57%8/6/2025 (Estimated)SEERSeer-$86.28M-$1.41N/AN/AN/A-565.83%-21.96%-19.85%8/14/2025 (Estimated)Latest SEER, EYPT, QSI, and LAB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025QSIQuantum-Si-$0.17-$0.11+$0.06-$0.11$0.96 million$0.84 million5/13/2025Q1 2025SEERSeer-$0.37-$0.34+$0.03-$0.34$3.25 million$4.21 million5/7/2025Q1 2025EYPTEyePoint Pharmaceuticals-$0.65-$0.65N/A-$0.65$8.84 million$24.50 million3/5/2025Q4 2024EYPTEyePoint Pharmaceuticals-$0.54-$0.64-$0.10-$0.64$11.02 million$11.60 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEYPTEyePoint PharmaceuticalsN/AN/AN/AN/AN/ALABStandard BioToolsN/AN/AN/AN/AN/AQSIQuantum-SiN/AN/AN/AN/AN/ASEERSeerN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEYPTEyePoint PharmaceuticalsN/A5.505.45LABStandard BioToolsN/A3.763.41QSIQuantum-SiN/A13.4213.15SEERSeerN/A18.3617.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEYPTEyePoint Pharmaceuticals99.41%LABStandard BioTools53.74%QSIQuantum-Si39.90%SEERSeer75.20%Insider OwnershipCompanyInsider OwnershipEYPTEyePoint Pharmaceuticals4.74%LABStandard BioTools23.16%QSIQuantum-Si30.04%SEERSeer15.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEYPTEyePoint Pharmaceuticals12068.81 million65.02 millionOptionableLABStandard BioTools620379.82 million174.59 millionOptionableQSIQuantum-Si150183.50 million99.84 millionOptionableSEERSeer16058.87 million50.12 millionOptionableSEER, EYPT, QSI, and LAB HeadlinesRecent News About These CompaniesAbu Dhabi's Al Seer Marine sets up tanker JV, secures $57mln ADCB term loanJune 2 at 2:47 AM | zawya.comProstate Cancer Surgery Rates Drop in Low-Risk CasesJune 1 at 3:04 PM | emjreviews.comDoc-turned-seer of Telugu origin to head Courtallam peethamJune 1 at 3:04 PM | msn.comSeer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea ...June 1 at 9:26 AM | bakersfield.comLearn Kannada and respect other languages: SeerJune 1 at 9:26 AM | starofmysore.comSeer, Inc. and Korea University Launch First Large-Scale Study to Identify Early-Onset Cancer Biomarkers Using Proteograph ONE AssayJune 1 at 7:41 AM | quiverquant.comSeer's Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young AdultsJune 1 at 7:00 AM | globenewswire.comSeer, Inc. (NASDAQ:SEER) Stake Raised by Two Sigma Advisers LPJune 1 at 3:59 AM | marketbeat.comBulldozers raze illegal ashram of arrested self-styled seerMay 31 at 2:26 AM | thehansindia.comSeer Jagadguru Rambhadracharya seeks PoK as ‘guru dakshina’ from Army chief general Upendra DwivediMay 30 at 9:26 PM | msn.comKarnataka Demolishes 'Illegal' Ram Mandir Mutt After Seer’s ArrestMay 30 at 6:50 AM | msn.comMan Group plc Has $38,000 Stake in Seer, Inc. (NASDAQ:SEER)May 30 at 3:44 AM | marketbeat.com‘Want PoK back as dakshina’: Seer told Army Chief DwivediMay 30 at 1:50 AM | thehansindia.comMutt demolished in Raibag after seer’s arrest in Pocso caseMay 30 at 1:50 AM | timesofindia.indiatimes.comIllegal Ram Mandir in Karnataka's Belagavi demolished after seer held for abduction, rapeMay 30 at 1:50 AM | msn.comAsked for Pakistan-occupied Kashmir as gurudakshina from Army staff chief Dwivedi, says UP seerMay 29, 2025 | deccanherald.comHindu seer Rambhadracharya seeks PoK as Guru Dakshina from Army Chief DwivediMay 29, 2025 | msn.comSeer demands PoK in guru dakshina from Army ChiefMay 29, 2025 | msn.comSeer Redefining Deep Unbiased Proteomics with Launch of New Proteograph Workflow at ASMS 2025, Enabling Previously Unattainable Scale and EfficiencyMay 29, 2025 | globenewswire.comYounger Adults See Rising Pancreatic & Colorectal Cancer RatesMay 27, 2025 | targetedonc.comPuri seer’s security to be enhancedMay 25, 2025 | thehansindia.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSEER, EYPT, QSI, and LAB Company DescriptionsEyePoint Pharmaceuticals NASDAQ:EYPT$7.42 +0.18 (+2.49%) Closing price 04:00 PM EasternExtended Trading$7.42 0.00 (0.00%) As of 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.Standard BioTools NASDAQ:LAB$1.05 +0.04 (+3.96%) Closing price 04:00 PM EasternExtended Trading$1.05 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Standard BioTools Inc., together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument. It also provides genomics, such as X9 Real-Time PCR System, a real-time PCR analytical instrument including pre-processing steps for microfluidics-based workflows using (integrated fluidic circuit) IFCs; and IFC Controllers, a controller which is designed to work with IFC formats. In addition, the company offers analytical instruments comprising Biomark HD system, a real-time PCR analytical instrument for microfluidics-based workflows using prepared IFCs. It sells its products to academic research institutions; translational research and medicine centers; cancer centers; clinical research laboratories; biopharmaceutical, biotechnology, and plant and animal research companies; and contract research organizations. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Fluidigm Corporation was incorporated in 1999 and is headquartered in South San Francisco, California.Quantum-Si NASDAQ:QSI$1.68 0.00 (0.00%) Closing price 04:00 PM EasternExtended Trading$1.68 +0.01 (+0.30%) As of 04:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company's platform is comprised of the Platinum NGPS instrument; the Platinum Analysis Software service; and reagent kits and semiconductor chips for use with its instruments. It is used in protein identification, protein variants, antibody characterization, biomarker identification, and post translational modification analysis applications. The company was founded in 2013 is headquartered in Branford, Connecticut.Seer NASDAQ:SEER$2.14 +0.22 (+11.46%) Closing price 04:00 PM EasternExtended Trading$2.14 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Will Hit $360 Soon: Here’s the How and Why Buy The Dip in Okta, There’s Nothing Wrong With the Outlook Why SoundHound Could Be a Short Squeeze in the Making Why Schwab US Dividend Equity ETF Could Lead the Rotation Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell 5 Reasons Costco Stock Will Hit New Highs This Year Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
